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ABSTRACT 
Objectives: To investigate and evaluate the transdermal delivery of ethosomes bearing vancomycin hydrochloride, a glycopeptide antibiotic with a 
relatively high molecular weight (1485.7Da). 
Methods: Vancomycin loaded ethosomes were prepared by cold method technique and characterized for vesicular shape, vesicular size, 
entrapment efficiency, zeta potential, in vitro drug permeation, microbiological assay against methicillin resistant Staphylococcusaureus (MRSA) 
and stability.  
Results: Microscopic examinations suggested ethosomes as unilamellar spherical vesicles. Vesicle size, entrapment efficiency and zeta potential 
values were depending on concentration of membrane components. Ethosomal formula having 1% phospholipid, 45% ethanol and 10% propylene 
glycol (F13) showed the smallest mean particle size (71.60nm±17.6) and highest transdermal flux (414.7 µg/cm2. hr) across hairless rat skin which 
was 72.67 times drug solution. The results obtained from microbiological assay suggested that the minimum inhibitory concentration (MIC) is 
affected by surface charge of ethosomes. The optimized formula on storage at 4°C for 90 days retained 89.82%±1.00 of initial drug content.  
Conclusions: The results collectively suggest that ethosomes are efficient carrier for transdermal delivery of vancomycin hydrochloride. 
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INTRODUCTION 
Transdermal delivery has potential advantages over other routes of 
administration. It could reduce first-pass metabolism associated 
with oral delivery and is less painful than injections. However, the 
outermost layer of the skin, the stratum corneum (SC), limits passive 
diffusion to small lipophilic molecules. Therefore, methods are 
needed to safely permeabilize the SC so that ionic and larger 
molecules may be delivered transdermally [1]. Many techniques have 
been aimed to disrupt and weaken the highly organized intercellular 
lipids in an attempt to enhance drug transport across the intact skin. One 
of the most controversial methods is the use of vehicle formulations as 
skin delivery systems. Even though, some authors suggested that 
conventional lipid-based suspensions such as liposomes, niosomes, and 
micro-emulsions, which have also been proposed as low- risk drug 
carriers, do not offer much value in transdermal drug delivery because 
they do not deeply penetrate the skin, but rather remain on the upper 
layers of skin strata in addition to poor stability [2], researchers 
introduced modified forms of vesicular systems which exhibited better 
transdermal permeation and stability [3].  
Ethosomes are noninvasive delivery carriers that enable drugs to 
reach the deep skin layers and/or the systemic circulation. These are 
soft, malleable vesicles tailored for enhanced delivery of active 
agents. They are composed mainly of phospholipids, high 
concentration of ethanol and water. Ethosomes are the best 
alternative to liposomes and transferosomes as ethanol overcome 
the problem of entering to SC by increasing penetration rate [4].  
Vancomycin hydrochloride is a glycopeptide antibiotic used in the 
prophylaxis and treatment of infections caused by gram-positive 
bacteria [5]. Vancomycin is bactericidal by binding to the 
transglycosylase/transpeptidase complex of enzymes that are 
responsible for the last stages of bacterial cell wall formation [6]. 
Vancomycin is currently available in the market as parenteral 
infusion. The only indication for oral vancomycin therapy is in the 
treatment of pseudo membranous colitis. Inhaled vancomycin has 
also been used (off-label), via nebulizer, for treatment of various 
infections of the upper and lower respiratory tract [7].  
Research work involves topical application of vancomycin was 
mainly restricted to the situation where the main permeation 
barrier is damaged as in cases of skin wounds and ulcers [8-10]. 
Some trials are found in order to examine the ability of some 
delivery system to transport vancomycin across intact biological 
barrier, where Jun [11] studied transdermal iontophoresis of 
vancomycin to infectious disease in orthopedics. The present work 
was focused on evaluating the potential of ethosomes in transdermal 
delivery of macromolecules, and to formulate a new delivery system 
of vancomycin drug capable of providing sustained and controlled 
release of the drug. 
MATERIALS AND METHODS 
Materials 
Vancomycin hydrochloride was a gift from Sigma tec, Egypt. Soy 
phosphatidylcholine and Stearylamine were purchased from Sigma –
Aldrich, USA. Potassium dihydrogen phosphate, Disodium hydrogen 
phosphate and Sodium chloride were purchased from El- Nasr 
Pharmaceutical Co., Egypt. All other reagents and solvents were of 
analytical grade. 
Methods 
Preparation of ethosomes 
Vancomycin hydrochloride ethosomes was prepared by cold method 
[12]. The ethosomal system of vancomycin hydrochloride was 
comprised of 1–3 % w/v soy phospholipids (SPC), 30 – 45 % v/v of 
ethanol and water up to 100% v/v. SPC was dissolved in ethanol 
together with 250 mg of vancomycin hydrochloride. The mixture 
was heated to 30°C in water bath. Distilled water is added slowly in 
a fine stream with a constant mixing using mechanical stirrer, at 700 
rpm in a closed vessel. The temperature was maintained at 30°C 
during the experiment. The mixing was continued for 5 minutes. 
Ethosomes suspensions were transferred to a 15 ml centrifuge tube. 
The suspension was centrifuged at 13,000 rpm for 1 hour at 4°C 
using a cooling centrifuge (Sigma 3K 30, Germany), then re 
suspended in PBS. The preparation was stored at 4°C. 
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Preparation of modified ethosomes 
For the selected formula stearylamine (SA) in 0.4% and 0.8% or 
propylene glycol (PG) in 5 and 10% was added as shown in table (1). 
For PG formulae, a modified method was used where PG was added 
to distilled water before mixing with the organic phase. On the other 
hands, SA formulae, SA was mixed with SPC and dissolved in ethanol 
together with 250 mg of vancomycin hydrochloride before adding 
aqueous phase. The remaining steps of the preparation process were 
followed as mentioned above. 
Characterization of ethosomes 
Electron microscopy 
Ethosomal vesicles were visualized using transmission electronic 
microscopy (Hitachi H-7500 80kVJapan), with an accelerating 
voltage of 80 kV.  
Determination of entrapment efficiency (EE) 
Vancomycin hydrochloride ethosomes suspensions were transferred 
to a 15 ml centrifuge tube. The suspension was centrifuged at 13,000 
rpm for 1 hour at 4°C using a cooling centrifuge (Sigma 3K 30, 
Germany). Following centrifugation, the sediment was lysed using 
methanol and analyzed spectrophotometrically by measuring the U. 
V. absorbance at 280.20 nm using-U. V- Visible Spectrophotometer, 
Model UV- 1650 P. C (Shimaduzu, Japan).  
The encapsulation or entrapment efficiency was determined relative 
to the original drug concentration added, applying the following 
equation.  
%E=ED/TDX100  
Where % E is the percent encapsulation efficiency, ED is the 
concentration of entrapped drug and TD is the total drug 
concentration. 
Particle size analysis and Zeta potential measurement 
The vesicle size and zeta potential was measured by Malvern 
zetasizer (V.6.010: Malvern instrument L. D. T Malvern UK) 
In vitro skin permeation study  
The in vitro skin permeation of vancomycin hydrochloride was 
studied using locally fabricated Franz’s diffusion cell with an 
effective permeation area and receptor cell volume of 3.14 cm2and 
30 mL, respectively. The temperature of the receiver vehicle (PBS, 
pH 7.4) was maintained at 37±1°C and was constantly stirred by a 
magnetic stirrer at 100 rpm. The rat skin was subsequently carefully 
checked through a magnifying glass to ensure that samples were 
free from any surface irregularity such as tiny holes or services in 
the portion that was used for transdermal permeation studies. The 
skin was later mounted on a receptor compartment with the SC side 
facing toward the donor compartment. An amount of ethosomes 
equivalent to 150 mg of vancomycin hydrochloride was placed in the 
donor compartment. Samples of 0.5 ml were withdrawn from the 
receptor compartment every hour for 12 hour then immediately 
analyzed by UV spectrophotometer. The receptor phase was 
immediately replenished with equal volume of fresh diffusion buffer. 
Similar experiments were performed with PBS of pure drug sample. 
Permeation data analysis  
The permeation profile conducted by plotting the cumulative 
amount of permeated drug (μg/cm2) versus time (hr), the steady 
state flux Jss(μg/cm2. hr) was calculated from the slope of the linear 
portion, permeability coefficient [kp] was calculated by dividing [Jss] 
by the employed concentration of the drug (Co) according to the 
equation: Kp= Jss/ Co.  
Microbiology study 
The effect of incorporation vancomycin hydrochloride into 
ethosomal formulation upon the minimum inhibitory concentration 
was studied using critical dilution method and disc diffusion assay 
[13]. The disc, which is used in the experiment, was saturated with 
15 µl. The count of staphylococcus aureus MRSA was 1.6 x 108 
cfu/ml, the test was performed using Mueller-Hinton agar and the 
plates were incubated on 37ºC /24-48 h, the experiment was 
conducted in triplicate. 
Stability studies 
Stability studies were carried out by storing out the ethosomal 
formulation at 4ºC for 90 days. The drug content was estimated to 
identify any change in the entrapment efficiency of ethosomal 
formulae. 
Statistical analysis of data  
To investigate the significance difference between the results of 
studied formulae, the one way analysis of variance (ANOVA) test 
was used. The level of significance was set at   0.05, and (*p<0.05) 
was considered to be statistically significant. 
RESULTS AND DISCUSSION 
Visualization of vesicles 
Electron microscopy showed that ethosomes vesicles were 
unilameller and of a spherical shape as shown in fig. 1.  
 
Fig. 1: Visualization of vesicles by transmission electron 
microscopy 
 
Entrapment efficiency  
Entrapment efficiency was found to increase with increasing ethanol 
concentration this may be related to co-solvent effect of ethanol; 
therefore, the more drug amount could be accommodated into the 
aqueous core of the vesicles. Increase in SPC concentration showed 
increase in drug entrapment as shown as in table (1). Addition of PG 
led to a significant decrease in entrapment efficiency. This is may be 
due to the poor solubility of vancomycin hydrochloride in PG [14], 
also this is may be attributed to the fact that increasing the 
concentration of permeation enhancer, the fluidity of bilayer also 
increased causing the drug to leach out of vesicles. Addition of SA a 
cationic surfactant led to a significant increase in entrapment 
efficiency. This result was attributed to the long stearyl chain (C18) 
inserted into the lipid bilayers which become tighter leading to 
decreasing the elasticity and increasing rigidity of vesicle and 
consequently lower permeability to the entrapped drug and hence, 
higher entrapment efficiency was observed. 
Particle size analysis 
The size of the vesicles was increased with increasing phospholipids 
concentration. This could be attributed to the fact that SPC confers 
greater rigidity to vesicle consequently reducing vesicle fusion. By 
increasing ethanol concentration the vesicular size decreased. This 
indicates that at higher ethanol concentration the membrane 
thickness is reduced considerably, probably due to the formation of 
a phase with interpenetrating hydrocarbon chain. These results are 
in agreement with previous research studies [15-17]. Incorporation 
of PG resulted in reduction in vesicle size. This suggests an 
interaction of PG with the phospholipid bilayer where the enhancer 
interpenetrates the SPC hydrocarbon chain allowing more bilayer 
flexibility and smaller vesicle size. Incorporation of SA led to 
significant increase in particle size. This may attributed to the fact 
that inclusion of surface charge inducer (SA) in the lipid bilayer 
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increased the spacing between the bilayers and led to a rise of the 
internal aqueous compartment, also the charge inducer was found to 
enhance significantly the amount of drug entrapped into the 
vesicles. This result was in accordance with Nikoofal-Sahlabadi et al 
[18] who observed an increase in vesicle size upon addition of SA. 
Zeta potential measurement  
Zeta potential is an important parameter that affects the aggregation 
of vesicles and depicts the physical stability of vesicular systems. 
High zeta potential prevents the aggregation between vesicles and 
hence, enhances its physical stability [19]. Ethosomal formulae 
exhibited negative charge ranging from (-29.3 mv to- 53.1 mv).  
The zeta potential value was increased by increasing SPC and 
ethanol concentration, this was attributed to (i) ethanol, which 
provides a net negative surface charge thus avoiding aggregation of 
vesicles due to electrostatic repulsion; and (ii) SPC, which provides a 
greater rigidity to the layers and reduced likelihood of vesicles 
fusion carry a negative charge likely due to ionization of phosphate 
group resulting in a high negative charge. Incorporation of PG 
resulted in higher zeta potential values.  
This result agrees with Pandey [20] who concluded that PG induced 
a transition in the charge of the vesicles to more negative values. 
Incorporation of SA led to shift in the surface charge of the vesicles 
from negative charge to positive one. These results indicate the 
association of SA molecules at the vesicle surface. 
 











Average vesicular size± S. D 
(nm) 
Zeta potential ±S. D 
(mv) 
F1 1 30 - - 63.24±0.95 183.5±18.45 -29.3±2.85 
F2 2 30 - - 67.06±0.10 185.2 ±8.80 -35.5±0.60 
F3 3 30 - - 69.73±0.09 250.8±16.1 -47.3±2.25 
F4 1 40 - - 67.69±0.74 136.0±16.1 -33.4±1.53 
F5 2 40 - - 70.55±0.81 139.7±8.50 -48.9±0.10 
F6 3 40 - - 75.64±0.47 201.1±9.90 -49.9±0.83 
F7 1 45 - - 71.96±0.70 105.3±11.2 -44.2±1.65 
F8 2 45 - - 77.81±0.73 116.2±5.50 -53.1±1.40 
F9 3 45 - - 78.23±0.41 153.6±20.9 -49.5±0.94 
F10 1 45 0.4 - 80.26±0.35 153.9±6.80 +37.1±0.98 
F11 1 45 0.8 - 89.79±0.46 195.3±10.70 +48.1±1.10 
F12 1 45 - 5 55.85±0.95 103.0±9.45 -48.1±1.50 
F13 1 45 - 10 48.95±0.64 71.60±17.6 -50.5±2.00 
 
In-vitro permeation studies  
The Transdermal penetration of vesicles is determined by vesicle 
size, where the penetration abilities of permeate are inversely 
related to the size of ethosomes and vesicles smaller than 300 nm 
are able to deliver the permeate into deeper skin layers efficiently, 
other factors affecting drug permeation from ethosomes are surface 
charge, elasticity and composition of vesicle bilayer. The value of 
transdermal flux depends on the ethanol concentration. As the 
concentration of ethanol increased, flux value of vancomycin 
hydrochloride increased. Formulae F2, F5and F 8 containing same 
percent of SPC 2% w/v whereas increasing ethanol concentration 
from 30 % v/v to 40 and 45%v/v respectively leading to enhancing 
transdermal flux from 169.8 ug/cm2/hr to195.3 ug/cm2/hr and 
221.2 ug/cm2/hr. This result is supported by the observation of 
zidovudine-loaded ethosome made by Jain et al [21]. The data 
suggested that the transdermal flux of zidovudine increased with 
increasing ethanol concentration.  
When SPC concentration increased, there was increase in drug 
permeation but when SPC concentration exceeded 2% w/v there 
was a subsequent decrease in permeation of vancomycin 
hydrochloride from ethosomes. These results indicate that if the 
percentage of SPC exceeded 2%w/v, bilayer deformability of 
vesicles occurred with subsequent reduction in permeation drug 
from ethosomes. This result is in accordance with Barupal et al [22] 
who found that when the percentage of SPC exceeded 2w/v% there 
was reduction in permeation of aceclofenac from ethosomes and 
attributed that to decrease in the bilayer deformability of vesicles. 
In spite that skin is negatively charged under the physiological 
conditions and we assume that by imparting a positive charge on 
vesicles surface using SA that will enhance the drug permeation 
across the skin, unfortunately, vancomycin hydrochloride release 
decreased as the percentage incorporated of SA increased. The 
steady state flux of F7 was 222.1 ug/cm2/hr on adding 0.4% v/w SA 
(F10) the value is reduced to 192.1 ug/cm2/hr and further increase 
in SA percentage to be 0.8% w/v (F11) was followed by decrease in 
flux value to become 120.4 ug/cm2/hr. This result was attributed to 
the long stearyl chain inserted into the lipid bilayers that led to a 
lower permeability to the entrapped drug.  
Addition of PG into composition of F7 in 5 and 10% v/v led to an 
increase in drug permeability through rat skin, where PG acts as 
permeation enhancer, which increases permeability of vesicle 
through biological membrane due to synergistic effect with ethanol 
on bilayer of the vesicles. In addition to increasing the deformability 
of vesicles, extraction of intercellular lipids, increasing SC hydration, 
alteration of proteinaceous corneocyte components. These results is 
in agreement with Zhaoa et al [23] who compared vesicles 
containing PG with traditional ethosomes and concluded that PG 
vesicles showed better transdermal efficiency than ethosomes. 
Antimicrobial activity of free and ethosomal vancomycin 
hydrochloride 
The minimum inhibitory concentration (MIC) of vancomycin 
hydrochloride loaded ethosomes compared with free antibiotics 
against staphylococcus aureus MRSA (ATCC43300) are shown in fig. 
(2and3) and table (3). Ethosomal formulae F12 and F13 showed MIC 
value equal to MIC of free drug. However, the cationic ethosomal 
formulae F10 and F11 yielded MIC value (2.44 µg/ml) lower than 
MIC obtained with the free drug. Such enhancement could be 
explained on the basis that, in cationic formulae adsorption of 
cationic vesicles onto bacterial cells changes the sign of the cell 
surface from negative to positive with a clear relationship between 
positive charge on bacterial cells and cell death.  
 
 
Fig. 2: The effect of drug encapsulation into vesicular system on 
minimum inhibitory concentration of vancomycin 
hydrochloride 
Table 2: Permeation parameters of vancomycin hydrochloride from different formulae through hairless rat skin 




Free drug 85.33±0.99 5.706 0.000038 
F1 596.27±0.96 37.37 0.000249 
F2 1978.83±0.83 169.8 0.001126 
F3 337.09±0.94 20.57 0.000137 
F4 1010.11±0.76 50.94 0.000339 
F5 2516.9±0.89 195.3 0.001302 
F6 571.10 ±0.83 46.97 0.000313 
F7 2525.48±0.60 222.1 0.001480 
F8 2585.12±0.69 221.2 0.001474 
F9 2119.70±0.86 200.0 0.001333 
F10 2244.22 ±0.77 192.1 0.001280 
F11 1409.14±0.63 120.4 0.000802 
F12 3008.47±0.64 277.0 0.001846 
F13 4390.55±0.51 414.7 0.002764 
 
Table 3: The minimum inhibitory concentration of free vancomycin hydrochloride and ethosomal formulae 
Formulae MIC (µg/ml) 






This result is in agreement with Gubernator et al [24] who found 
that cationic formulations exhibit significantly higher bactericidal 
efficacy than anionic and neutral vesicles, regardless the type of 
drug and concluded that the MIC antimicrobial efficacy is not 
correlated to rapid drug release from vesicular system but rather to 
electrostatic interaction between the vesicle and bacterial cell. 
 
 
Fig. 3: Disk diffusion method showing MIC of (a) free drug, (b) 
F10 and (c) F13 
Stability 
Table 4 and fig. (4) presented the effect of storage conditions on the 
amount of drug entrapped by the end of the study. Propylene glycol 
PG showed a promising effect on the stability of ethosomes. The 
percentage of entrapped drug in F13 was significantly increased 
than non-PG ethosomes F7. These results suggest a stabilizing effect 
of PG in the formulations against aggregation of vesicles by 
providing a net negative charge on their surface. These results were 
in agreement with Elmoslemany et al [25] who found that the drug 
leakage was more evident in conventional liposomes compared to 
the ones containing PG. On the other hand, SA exhibited an 
undesirable effect on stability of ethosomes as shown in F10. 
However, the encapsulated drug tends to leak out from the bilayer 
structure during storage in all formulations. This could be attributed 
to phospholipid leakage from the ethosomes bilayers which led to 
the formation of pores that increased drug leakage [26]. 
 
Table 4: Effect of storage for 90 days at refrigerated 
temperature of ethosomes on drug content 
Formulae Initial 
concentration 
% Residual drug content after 
storage for 90th days 
F7 100 81.88±0.55 
F10 100 77. 67±1.20 
F13 100 89.82±1.00 
 
% Residual drug content  
 
Fig. 4: Effect of storage for 90 days at refrigerated temperature 
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CONCLUSION 
The results demonstrate that ethosomes is an efficient noninvasive 
tool for transdermal delivery of vancomycin hydrochloride, the 
entrapment efficiency, particle size and zeta potential values were 
mainly dependant on vesicular components. The addition of 
permeation enhancer PG to selected formula enhance the 
transdermal flux, reduce particle size, did not alter the MIC of drug 
and stabilize the formula against drug leakage on storage but reduce 
entrapment efficiency of drug, while the addition of cationic 
surfactant led to significant reduction in drug permeation, increase 
particle size and lesser drug retention on storage but surprisingly 
lowered the MIC compared to free drug and increase entrapment 
efficiency. The study is a platform in formulating delivery system 
capable of delivering vancomycin hydrochloride transdermally.  
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